Sana Biotechnology Announces Promising Follow-Up Publication in The New England Journal of Medicine on Gene-Edited Islet Therapy for Type 1 Diabetes

A significant advancement in the quest for a functional cure for Type 1 Diabetes (T1D) has been detailed in a new publication within the prestigious The New England Journal of Medicine. The report elaborates on the remarkable progress of the first individual to receive Sana Biotechnology’s gene-edited islets, who continues to produce insulin over 14 months post-transplant, a groundbreaking achievement that has been accomplished without the need for immunosuppressive drugs. This development marks a crucial step forward in cell therapy for T1D, addressing the long-standing challenge of immune rejection that has hampered previous therapeutic efforts.

The Genesis of Sana’s Hypoimmune Cell Therapy

Sana Biotechnology’s innovative cell therapy approach centers on a novel strategy designed to shield transplanted islet cells from the body’s immune system, thereby enabling them to persist and continue their vital function of insulin production. The core of this technology lies in advanced gene editing techniques employed to engineer "hypoimmune" islet cells. These cells are specifically modified to evade immune system recognition while retaining their critical capacity to synthesize and secrete insulin. This pioneering strategy aligns with the broader research priorities of organizations like Breakthrough T1D, which is actively championing next-generation cell therapies aimed at overcoming the formidable barrier of immune rejection in T1D treatment.

The journey of this therapy began with deceased-donor islets, which were subjected to sophisticated gene editing processes. The objective was to render them invisible to the immune system’s surveillance mechanisms, a critical step in preventing their destruction after transplantation. These modified islets were then transplanted into the forearm of a participant. This initial human trial, classified as a Phase 1 study, was primarily designed to evaluate the safety profile of the therapy. Concurrently, researchers meticulously monitored the functional capacity of the transplanted islets by measuring C-peptide levels. C-peptide is a reliable biomarker that reflects the body’s endogenous insulin production, serving as a direct indicator of the transplanted cells’ viability and activity.

It is important to note the exploratory nature of this initial study. The transplanted islet cell dose represented approximately 5% of the cell count typically required to fully restore insulin independence in individuals with T1D. This deliberate approach allowed researchers to assess the fundamental principles of immune evasion and functional persistence at a lower cellular burden, minimizing potential risks while gathering essential preliminary data.

Unveiling the Early Results: A Beacon of Hope

The findings reported thus far are exceptionally encouraging, offering substantial evidence of the therapy’s potential. Over a follow-up period of 60 weeks, the participant experienced no severe adverse events, successfully meeting the primary safety endpoint of the clinical trial. This is a critical milestone, as safety is paramount in early-stage human studies.

At the 14-month mark post-transplantation, the participant continued to exhibit detectable levels of C-peptide. This sustained presence of C-peptide is a powerful testament to the transplanted islets remaining alive and functional within the recipient’s body. Further validation of their presence and activity was provided through advanced imaging techniques, including Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI), which visualized the islet cells within the participant’s forearm.

Researchers also observed an intriguing fluctuation in C-peptide levels. Approximately one year after transplantation, a temporary decline in C-peptide was noted, which the researchers attributed to potential beta-cell exhaustion – a phenomenon where insulin-producing cells may experience reduced function due to sustained high demand. However, this decline was followed by a subsequent recovery in C-peptide levels, a development that researchers view as a particularly encouraging signal. This recovery suggests that the transplanted cells possess a remarkable capacity to regain their functional state, even after periods of stress.

Crucially, the participant demonstrated no discernible immune response directed against the transplanted islet cells. While pre-existing T1D autoantibodies, which are indicative of the autoimmune attack that characterizes T1D, remained unchanged and did not impact the survival or function of the gene-edited islets. This observation reinforces the efficacy of Sana’s hypoimmune engineering strategy in shielding the transplanted cells from immune attack, even in the presence of an ongoing autoimmune environment.

The Path Forward: Scaling Up and Broadening Access

While these results represent an early stage of investigation, they provide a robust proof-of-concept. The findings strongly suggest that gene-edited, immune-evasive islet cells can successfully survive and function within the complex biological environment of an individual with T1D. If these promising outcomes are replicated and validated in larger, more comprehensive clinical studies, this approach could significantly accelerate the field’s progress towards developing cell therapies that eliminate the need for long-term, broad immunosuppression—a central objective for achieving a functional cure for T1D.

In an exciting development that underscores Sana Biotechnology’s commitment to scalability, the company is actively preparing to translate its proprietary hypoimmune gene-editing technology to manufactured islets. This next phase will involve a new clinical trial focused on using islets produced in a laboratory setting, rather than those sourced from deceased donors. By combining their innovative immune protection strategy with a scalable manufacturing process, Sana aims to create a more accessible and sustainable therapeutic option for individuals with T1D. This initiative is directly aligned with Breakthrough T1D’s ambitious "Project ACT" (Accelerate Cell Therapies), a comprehensive program dedicated to dramatically expediting the development, accessibility, and widespread adoption of islet cell therapies for all individuals with T1D who can benefit from them.

Understanding Project ACT

The development of groundbreaking scientific advancements, particularly in complex fields like regenerative medicine, necessitates substantial time, resources, collaborative efforts, and dedicated scientific endeavor. Recognizing this, Breakthrough T1D launched Project ACT. This initiative is a strategic and multifaceted endeavor designed to simultaneously accelerate critical research, streamline product development pathways, optimize regulatory processes, and enhance patient access and adoption of islet cell therapies. A key focus of Project ACT is the development of therapies that do not require broad immunosuppression, a significant hurdle that has historically limited the widespread use of cell replacement strategies for T1D. By addressing these interconnected aspects, Project ACT aims to bring life-changing therapies to people with T1D faster than ever before.

Driving Innovation in T1D Cell Therapies: The Role of T1D Fund

Sana Biotechnology is a key portfolio company of the T1D Fund, a venture philanthropy fund established by Breakthrough T1D. Through strategic equity investments, the T1D Fund has played a pivotal role in fostering the growth and advancement of Sana’s T1D pipeline, directly contributing to the progression of their gene-edited islet cell therapy into human clinical trials.

The T1D Fund’s impact extends beyond a single company. Recently, the fund also invested in Century Therapeutics, another company actively engaged in the development of manufactured islet cell therapies that incorporate immune-evasive capabilities. This dual investment strategy highlights the T1D Fund’s commitment to supporting a diverse range of promising approaches aimed at overcoming immune barriers in T1D cell therapy. Breakthrough T1D, through the T1D Fund, remains dedicated to working collaboratively with Sana, Century Therapeutics, and other innovative companies. Their ongoing engagement focuses on providing crucial support for product development, accelerating the advancement of scalable islet cell therapy solutions, and ultimately working towards a future where T1D therapies do not necessitate immunosuppression. This commitment is vital for translating scientific breakthroughs into tangible benefits for the T1D community.